The prognostic impact of XRCC1 Arg399Gln polymorphism on prognosis of gastric cancer patients treated with platinum-based chemotherapy

Objective: To investigate the association of DNA X-ray repair cross complementary protein 1 (XRCC1) Arg399Gln polymorphism with the clinical outcome of gastric cancer patients treated with platinum-based chemotherapy. Methods: Eight-four patients with gastric cancer confirmed by pathological examination received postoperative combined chemotherapy (including platinum). Transcription of XRCC1 Arg399Gln was determined by polymerase chain reaction-ligation detection reaction (PCR-LDR). Results: Of the 84 patients, the frequencies of XRCC1 codon 399 Arg/Arg, Arg/Gln, and Gln/Gln genotype were 58.3% (49/84), 35.7% (30/84), and 6.0% (5/84), respectively; and the relapse and death rate were 63.1% (53/ 84) and 55.2% (43/84), respectively. The relapse and death rates in patients with Arg/Arg genotype were significantly lower than those in patients with Arg/Gln or Gln/Gln genotypes (P < 0.05). COX multivariate analysis showed that XRCC1 Arg399Arg polymorphism was associated with better recurrence-free and overall survival in gastric cancer patients compared with other genotypes (P < 0.05). Conclusion: Polymorphism of XRCC1 Arg399Gln correlated with the prognosis of gastric cancer patients treated with postoperative platinum-based chemotherapy. It may be helpful to a certain extent for evaluating the prognosis.